3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
UK-headquartered clinical-stage company OKYO Pharma’s today shared promising new categorical data analyses from the recent OK-101 Phase II trial in dry eye disease (DED) patients. 10 July 2024
The Sustainable Medicines Partnership (SMP), a collaborative of 48 organizations in the pharmaceutical and healthcare sectors, has published a report into wasted medicines. 10 July 2024
IDEAYA Biosciences (Nasdaq: IDYA) has announced a plan to raise about $263 million in a public share offering, which is expected to close around 11 July. 10 July 2024
Global growth in the pharma market will reach 7.7% through to the end of the decade, according to an analysis from industry commentator Evaluate. 10 July 2024
Lisbon-based Biovance Capital Partners, Portugal’s leading life sciences venture capital (VC) firm, has announced the first closing of its new biotech fund. 10 July 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the National Health Service (NHS) in England. 10 July 2024
The European authorities have granted marketing authorization for Livmarli (maralixibat), for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients from the age of three months. 10 July 2024
USA-based drug conjugates (ADCs) developer Sutro Biopharma
has appointed Barbara Leyman, as chief business development officer, effective July 8, 2024. 10 July 2024
A new report from the USA's Federal Trade Commission (FTC) underlines how the agency regards middlemen as having the potential to inflate drug prices. 10 July 2024
Immunic, a US biotech developing a pipeline of orally-administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has appointed experienced biopharma executive Jason Tardio as chief operating officer and president. 9 July 2024
During a speech on Tuesday, the UK’s new Secretary of State for Health and Social Care, Wes Streeting, said that he plans to boost the economy through the life sciences sector. 9 July 2024
Shares of Dutch gene therapy company uniQure were up more than 50% at $5.68, after the company released positive early clinical results for its Huntington’s disease candidate. 9 July 2024
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024
Stalicla, a privately-held Swiss biotech developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders such as autism spectrum disorder, has named Purnanand Sarma as chair of its board of directors. 9 July 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Abivax ABVX) today announced the results of an interim efficacy and safety analysis of an open-label maintenance (OLM) study that enrolled patients with ulcerative colitis (UC). 3 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.